Loading
Biotechnology
5 min read
Areas of Expertise :
Biochemistry, Biology, Genetics, Patent, Biotechnology
Published Date:
Last Modified Date:
Jurisdiction:
Federal. U.S. Supreme Court
Court:
The U.S. Supreme Court case Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), examined the scope of patent protection as it applies to biotechnology, gene patenting, and biochemistry. At the center of the case was the question of whether isolated human genes, specifically BRCA1 and BRCA2, genes linked to hereditary breast and ovarian cancer, could be patented. Myriad Genetics held patents on the isolated DNA sequences of these genes and related diagnostic methods, which influenced who could conduct testing and research using these sequences.
The case addressed the legal distinction between scientific discovery and technological invention, particularly in areas shaped by biochemistry and molecular biology. Biochemistry investigates the chemical makeup and interactions of biomolecules such as DNA, RNA, and proteins. These molecular insights are essential for understanding how genes operate and how they can be replicated or modified for medical use. The legal challenge raised broader questions about whether identifying and isolating a gene from the human body constitutes a patentable invention or a discovery of something naturally existing.
The ACLU and the Public Patent Foundation initiated legal action in the U.S. District Court for the Southern District of New York on behalf of medical associations, geneticists, and patients. The plaintiffs contended that genes, even when isolated, are natural products and therefore not patentable. They further argued that Myriad's patents limited access to genetic testing and constrained research in the field of hereditary disease.
Judge Robert W. Sweet ruled that isolated DNA is not eligible for patent protection under 35 U.S.C. §101. The court determined that the process of isolating a gene does not result in a new chemical composition, meaning it does not meet the standard for a patentable invention. This interpretation had implications for numerous biotechnology patents.
The U.S. Court of Appeals for the Federal Circuit partially reversed the district court’s decision. It ruled that complementary DNA (cDNA), which is synthesized in the lab through reverse transcription of messenger RNA, is patentable. However, the court agreed that isolated DNA identical to natural genetic sequences is not. The differing judicial opinions illustrated the complexity of interpreting patent law in relation to biochemical structures.
The Supreme Court unanimously held that naturally occurring DNA cannot be patented merely because it has been isolated from the human body. The Court stated that Myriad did not create or alter the genetic code in BRCA1 and BRCA2 but identified its location and sequence. However, the Court found that cDNA, which is not naturally occurring and must be constructed in a laboratory, is patent-eligible.
This decision clarified that for biological material to qualify for a patent, it must involve human-made alterations at the molecular level. The role of biochemistry in understanding and synthesizing cDNA was key to the Court’s distinction between natural discovery and inventive activity.
Supreme Court of the United States
Case Name:
Association for Molecular Pathology v. Myriad Genetics, Inc.
DNA sequencing technology
Genetic Testing
Molecular Biology
Patent Dispute
Patent Infringement
Laboratory Testing
The U.S. Supreme Court case Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), examined the scope of patent protection as it applies to biotechnology, gene patenting, and biochemistry. At the center of the case was the question of whether isolated human genes, specifically BRCA1 and BRCA2, genes linked to hereditary breast and ovarian cancer, could be patented. Myriad Genetics held patents on the isolated DNA sequences of these genes and related diagnostic methods, which influenced who could conduct testing and research using these sequences.
The case addressed the legal distinction between scientific discovery and technological invention, particularly in areas shaped by biochemistry and molecular biology. Biochemistry investigates the chemical makeup and interactions of biomolecules such as DNA, RNA, and proteins. These molecular insights are essential for understanding how genes operate and how they can be replicated or modified for medical use. The legal challenge raised broader questions about whether identifying and isolating a gene from the human body constitutes a patentable invention or a discovery of something naturally existing.
The ACLU and the Public Patent Foundation initiated legal action in the U.S. District Court for the Southern District of New York on behalf of medical associations, geneticists, and patients. The plaintiffs contended that genes, even when isolated, are natural products and therefore not patentable. They further argued that Myriad's patents limited access to genetic testing and constrained research in the field of hereditary disease.
Judge Robert W. Sweet ruled that isolated DNA is not eligible for patent protection under 35 U.S.C. §101. The court determined that the process of isolating a gene does not result in a new chemical composition, meaning it does not meet the standard for a patentable invention. This interpretation had implications for numerous biotechnology patents.
The U.S. Court of Appeals for the Federal Circuit partially reversed the district court’s decision. It ruled that complementary DNA (cDNA), which is synthesized in the lab through reverse transcription of messenger RNA, is patentable. However, the court agreed that isolated DNA identical to natural genetic sequences is not. The differing judicial opinions illustrated the complexity of interpreting patent law in relation to biochemical structures.
The Supreme Court unanimously held that naturally occurring DNA cannot be patented merely because it has been isolated from the human body. The Court stated that Myriad did not create or alter the genetic code in BRCA1 and BRCA2 but identified its location and sequence. However, the Court found that cDNA, which is not naturally occurring and must be constructed in a laboratory, is patent-eligible.
This decision clarified that for biological material to qualify for a patent, it must involve human-made alterations at the molecular level. The role of biochemistry in understanding and synthesizing cDNA was key to the Court’s distinction between natural discovery and inventive activity.
Described the molecular structure of DNA and emphasized that isolating DNA does not change its fundamental chemical nature. They explained that the separation process does not result in a new or altered molecule.
Provided information on techniques such as polymerase chain reaction (PCR), gel electrophoresis, and DNA sequencing. These experts outlined the laboratory processes used to study and manipulate genetic material.
Discussed the medical relevance of BRCA testing and the potential impact of gene patents on patient care and access. They presented perspectives on how exclusive rights to genetic information could affect the availability of diagnostic tools.
Offered insight into how patent law intersects with biotechnology. These witnesses evaluated the commercial and legal consequences of granting patents on genetic material, especially regarding innovation and market access.
Expert witnesses helped provide a factual framework for understanding how biochemical science relates to intellectual property principles. Their input supported the Court’s ability to assess the scientific nuances involved.
The Supreme Court’s ruling in Association for Molecular Pathology v. Myriad Genetics clarified the line between discovering a natural substance and inventing something new in the field of biotechnology. While acknowledging the importance of genetic research, the Court concluded that naturally occurring DNA sequences are not eligible for patent protection. In contrast, synthetic DNA such as cDNA, which does not occur in nature and involves human-led biochemical synthesis, may be patentable. This case illustrates how biochemistry and molecular biology inform legal interpretations of patent law. Expert testimony was instrumental in helping the Court differentiate between naturally occurring and human-engineered biological material.
Why was Myriad Genetics sued?
Myriad held patents that limited other laboratories from offering BRCA gene testing. The plaintiffs argued that these patents restricted access to medical services and constrained scientific research.
What did the Supreme Court decide?
The Court ruled that naturally occurring DNA is not patentable because it is a product of nature. However, cDNA, which is lab-created and differs from natural DNA, is considered eligible for patent protection.
How does this affect current biotech patent filings?
Patent applications in biotechnology must show clear human-driven modification to natural substances. This often includes altered DNA, engineered proteins, or developed diagnostic processes.
Were expert witnesses important to the case?
Yes. Expert witnesses in biochemistry, genetics, molecular biology, and patent law helped explain the differences between naturally occurring and synthetically produced DNA, contributing to the Court’s analysis.
Does this case affect CRISPR or gene-editing patents?
While this case focused on DNA isolation, its principles may be applied to future rulings involving technologies like CRISPR, where the distinction between natural material and human-engineered change is similarly important.
Described the molecular structure of DNA and emphasized that isolating DNA does not change its fundamental chemical nature. They explained that the separation process does not result in a new or altered molecule.
Provided information on techniques such as polymerase chain reaction (PCR), gel electrophoresis, and DNA sequencing. These experts outlined the laboratory processes used to study and manipulate genetic material.
Discussed the medical relevance of BRCA testing and the potential impact of gene patents on patient care and access. They presented perspectives on how exclusive rights to genetic information could affect the availability of diagnostic tools.
Offered insight into how patent law intersects with biotechnology. These witnesses evaluated the commercial and legal consequences of granting patents on genetic material, especially regarding innovation and market access.
Expert witnesses helped provide a factual framework for understanding how biochemical science relates to intellectual property principles. Their input supported the Court’s ability to assess the scientific nuances involved.
The Supreme Court’s ruling in Association for Molecular Pathology v. Myriad Genetics clarified the line between discovering a natural substance and inventing something new in the field of biotechnology. While acknowledging the importance of genetic research, the Court concluded that naturally occurring DNA sequences are not eligible for patent protection. In contrast, synthetic DNA such as cDNA, which does not occur in nature and involves human-led biochemical synthesis, may be patentable. This case illustrates how biochemistry and molecular biology inform legal interpretations of patent law. Expert testimony was instrumental in helping the Court differentiate between naturally occurring and human-engineered biological material.
Why was Myriad Genetics sued?
Myriad held patents that limited other laboratories from offering BRCA gene testing. The plaintiffs argued that these patents restricted access to medical services and constrained scientific research.
What did the Supreme Court decide?
The Court ruled that naturally occurring DNA is not patentable because it is a product of nature. However, cDNA, which is lab-created and differs from natural DNA, is considered eligible for patent protection.
How does this affect current biotech patent filings?
Patent applications in biotechnology must show clear human-driven modification to natural substances. This often includes altered DNA, engineered proteins, or developed diagnostic processes.
Were expert witnesses important to the case?
Yes. Expert witnesses in biochemistry, genetics, molecular biology, and patent law helped explain the differences between naturally occurring and synthetically produced DNA, contributing to the Court’s analysis.
Does this case affect CRISPR or gene-editing patents?
While this case focused on DNA isolation, its principles may be applied to future rulings involving technologies like CRISPR, where the distinction between natural material and human-engineered change is similarly important.
DNA sequencing technology
Genetic Testing
Molecular Biology
Patent Dispute
Patent Infringement
Laboratory Testing
Biotechnology, +4
Biotechnology